{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:43:44Z","timestamp":1789911824740,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"crossref"}]},{"name":"DGS"},{"name":"MSD"},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001009","name":"Bristol-Myers Squibb Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-3923-5","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T15:05:36Z","timestamp":1554217536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort"],"prefix":"10.1186","volume":"19","author":[{"name":"on behalf of the ANRS\/AFEF HEPATHER study group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9806-7953","authenticated-orcid":false,"given":"Anne","family":"Laurain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Metivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Haour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Larrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Dorival","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hezode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Marcellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bourliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Zarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Thabut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Alric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Ganne-Carrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bronowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Riachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Geist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Causse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Abergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chazouilleres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mathurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Guyader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Loustaud-Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ventzislava","family":"Petrov-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpha","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clovis","family":"Luzivika-Nzinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Carrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"issue":"5","key":"3923_CR1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/apt.12625","volume":"39","author":"ZM Younossi","year":"2014","unstructured":"Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39(5):518\u201331.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3923_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jhep.2007.09.010","volume":"48","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol. 2008;48(2):200\u20137.","journal-title":"J Hepatol"},{"issue":"2","key":"3923_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jhep.2008.04.012","volume":"49","author":"S Deuffic-Burban","year":"2008","unstructured":"Deuffic-Burban S, Deltenre P, Louvet A, Canva V, Dharancy S, Hollebecque A, et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol. 2008;49(2):175\u201383.","journal-title":"J Hepatol"},{"issue":"6","key":"3923_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","volume":"9","author":"LI Backus","year":"2011","unstructured":"Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509\u201316.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"24","key":"3923_CR5","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ Meer van der","year":"2012","unstructured":"van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama. 2012;308(24):2584\u201393.","journal-title":"Jama."},{"issue":"1","key":"3923_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","volume":"152","author":"P Nahon","year":"2017","unstructured":"Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152(1):142\u201356.e2.","journal-title":"Gastroenterology"},{"issue":"19","key":"3923_CR7","doi-asserted-by":"publisher","first-page":"7202","DOI":"10.1021\/jm100863x","volume":"53","author":"MJ Sofia","year":"2010","unstructured":"Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, et al. Discovery of a beta-d-2\u2032-deoxy-2\u2032-alpha-fluoro-2\u2032-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010;53(19):7202\u201318.","journal-title":"J Med Chem"},{"issue":"17","key":"3923_CR8","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1016\/j.bmcl.2008.07.088","volume":"18","author":"P Raboisson","year":"2008","unstructured":"Raboisson P, de Kock H, Rosenquist A, Nilsson M, Salvador-Oden L, Lin TI, et al. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3\/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett. 2008;18(17):4853\u20138.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"3923_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/hep.20032","volume":"39","author":"F Penin","year":"2004","unstructured":"Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology (Baltimore, Md). 2004;39(1):5\u201319.","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"20","key":"3923_CR10","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878\u201387.","journal-title":"N Engl J Med"},{"issue":"9956","key":"3923_CR11","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet (London, England). 2014;384(9956):1756\u201365.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"3923_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa1208953","volume":"368","author":"EJ Gane","year":"2013","unstructured":"Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34\u201344.","journal-title":"N Engl J Med"},{"issue":"3","key":"3923_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"20","key":"3923_CR14","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879\u201388.","journal-title":"N Engl J Med"},{"issue":"3","key":"3923_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1306227","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222\u201332.","journal-title":"N Engl J Med"},{"issue":"17","key":"3923_CR16","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604\u201314.","journal-title":"N Engl J Med"},{"key":"3923_CR17","doi-asserted-by":"crossref","unstructured":"Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, et al. Simeprevir plus Sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology (Baltimore, Md). 2016;64(2):370\u201380.","DOI":"10.1002\/hep.28467"},{"key":"3923_CR18","doi-asserted-by":"crossref","unstructured":"Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology (Baltimore, Md). 2015;64(2):360\u201369.","DOI":"10.1002\/hep.28422"},{"issue":"2","key":"3923_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","volume":"67","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67(2):263\u201371.","journal-title":"J Hepatol"},{"issue":"27","key":"3923_CR20","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599\u2013607.","journal-title":"N Engl J Med"},{"issue":"22","key":"3923_CR21","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"M Bourliere","year":"2017","unstructured":"Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"3923_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","volume":"63","author":"EASL","year":"2015","unstructured":"EASL. Recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199\u2013236.","journal-title":"J Hepatol"},{"key":"3923_CR23","unstructured":"AASLD. HCV guidance : Recommendations for testing, managing, and treating hepatitis C. 2015."},{"issue":"2","key":"3923_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"EASL","year":"2018","unstructured":"EASL. Recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461\u2013511.","journal-title":"J Hepatol"},{"issue":"2","key":"3923_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1053\/j.gastro.2015.10.013","volume":"150","author":"MS Sulkowski","year":"2016","unstructured":"Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, et al. Effectiveness of Simeprevir plus Sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2016;150(2):419\u201329.","journal-title":"Gastroenterology."},{"issue":"8","key":"3923_CR26","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/ajg.2015.218","volume":"110","author":"ML Shiffman","year":"2015","unstructured":"Shiffman ML, James AM, Long AG, Alexander PC. Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and\/or ribavirin. Am J Gastroenterol. 2015;110(8):1179\u201385.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"3923_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.27922","volume":"62","author":"V Saxena","year":"2015","unstructured":"Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, et al. Safety and efficacy of Simeprevir\/Sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology (Baltimore, Md). 2015;62(3):715\u201325.","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"5","key":"3923_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/apt.13300","volume":"42","author":"LI Backus","year":"2015","unstructured":"Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. veterans. Aliment Pharmacol Ther. 2015;42(5):559\u201373.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"3923_CR29","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/hep.27937","volume":"62","author":"BA Aqel","year":"2015","unstructured":"Aqel BA, Pungpapong S, Leise M, Werner KT, Chervenak AE, Watt KD, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology (Baltimore, Md). 2015;62(4):1004\u201312.","journal-title":"Hepatology (Baltimore, Md)"},{"key":"3923_CR30","unstructured":"Dieterich D, Bacon BR, Flamm SL. Evaluation of sofosbuvir and simeprevir-based regimens in the trio network: academic and community of a real-world, heterogenous population. Hepatology (Baltimore, Md). 2014;60(Suppl 1):220A\u2013220A."},{"key":"3923_CR31","doi-asserted-by":"crossref","unstructured":"Willemse SB, Baak LC, Kuiken SD, van der Sluys VA, Lettinga KD, van der Meer JT, et al. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life. J Viral Hepat. 2016;1\u20135.","DOI":"10.1111\/jvh.12567"},{"issue":"11","key":"3923_CR32","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1136\/gutjnl-2016-312012","volume":"66","author":"HR El-Khayat","year":"2017","unstructured":"El-Khayat HR, Fouad YM, Maher M, El-Amin H, Muhammed H. Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. Gut. 2017;66(11):2008\u201312.","journal-title":"Gut."},{"issue":"12","key":"3923_CR33","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1111\/liv.13470","volume":"37","author":"Z Marino","year":"2017","unstructured":"Marino Z, Pascasio-Acevedo JM, Gallego A, Diago M, Baliellas C, Morillas R, et al. High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. Liver Int. 2017;37(12):1823\u201332.","journal-title":"Liver Int"},{"issue":"1","key":"3923_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jhep.2016.08.021","volume":"66","author":"S Pol","year":"2017","unstructured":"Pol S, Bourliere M, Lucier S, Hezode C, Dorival C, Larrey D, et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol. 2017;66(1):39\u201347.","journal-title":"J Hepatol"},{"issue":"19","key":"3923_CR35","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMc1505967","volume":"373","author":"H Fontaine","year":"2015","unstructured":"Fontaine H, Lazarus A, Pol S, Pecriaux C, Bagate F, Sultanik P, et al. Bradyarrhythmias associated with Sofosbuvir treatment. N Engl J Med. 2015;373(19):1886\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"3923_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/gutjnl-2017-313869","volume":"67","author":"A Laurain","year":"2018","unstructured":"Laurain A, Kramer L, Sultanik P, Vallet-Pichard A, Sogni P, Pol S. Mortality associated with the treatment of HCV with direct-acting antivirals. Gut. 2018;67(1):197\u20138.","journal-title":"Gut"},{"issue":"3","key":"3923_CR37","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","volume":"59","author":"C Hezode","year":"2013","unstructured":"Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59(3):434\u201341.","journal-title":"J Hepatol"},{"issue":"1","key":"3923_CR38","doi-asserted-by":"publisher","first-page":"ofw258","DOI":"10.1093\/ofid\/ofx018","volume":"4","author":"I Alam","year":"2017","unstructured":"Alam I, Brown K, Donovan C, Forlenza J, Lauwers K, Mah'moud MA, et al. Real-world effectiveness of Simeprevir-containing regimens among patients with chronic hepatitis C virus: the SONET study. Open Forum Infect Dis. 2017;4(1):ofw258.","journal-title":"Open Forum Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3923-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-3923-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3923-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T23:07:58Z","timestamp":1585696078000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-3923-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3923"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-3923-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"assertion":[{"value":"22 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from each patient before enrolment. The protocol was performed in accordance with the Declaration of Helsinki and French law for biomedical research and was approved by the \u201cCPP Ile de France 3\u201d Ethics Committee (Paris, France) and the French Regulatory Authority (ANSM).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The ANRS CO22 HEPATHER cohort is sponsored and funded by Inserm-ANRS and conducted in collaboration with Association Fran\u00e7aise pour l\u2019\u00e9tude du Foie (AFEF). The cohort received supports from ANR (Agence Nationale de la Recherche), DGS (Direction G\u00e9n\u00e9rale de la Sant\u00e9) and MSD, Janssen, Gilead, Abbvie, BMS, Roche. The public\/private partnership is built in total transparency through a specific contract. The pharmaceutical companies are not involved in the scientific decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"300"}}